Hepatitis C in European prisons: a call for an evidence-informed response.
Hepatitis C in European prisons: a call for an evidence-informed response.
复制标题
欧洲监狱中的丙型肝炎：呼吁采取基于证据的应对措施。
DOI：
10.1186/1471-2334-14-s6-s17
复制
发表时间：
2014
影响因子：
3.7
通讯作者：
Stöver H
中科院分区：
文献类型：
--
作者：
Arain A;Robaeys G;Stöver H
在全球范围内，任何时候都有1 000多万人被关押在监狱和其他拘留场所。注射毒品者占男性囚犯的10-48%，占女性囚犯的30-60%。丙型肝炎在监狱中的传播显然是由注射毒品造成的，许多受感染的囚犯不知道自己的感染状况。在许多监狱环境中，通过普遍使用注射设备感染丙型肝炎的风险行为很普遍。在监禁环境中，社区适用的有效和高效预防模式很少得到实施。全世界10 000多所监狱中只有大约60所提供针头交换服务。因此，HCV预防几乎完全限于口头建议、传单和其他旨在改变认知行为的措施。虽然HCV抗病毒治疗的结果与非物质使用者和出狱后的物质使用者相当，但抗病毒治疗的接受率极低。基于文献综述，以评估丙型肝炎在囚犯中的传播，并了解更多有关监狱系统的影响，本文提出了关于监狱丙型肝炎预防，筛查和治疗的建议。
Globally, over 10 million people are held in prisons and other places of detention at any given time. People who inject drugs (PWID) comprise 10-48% of male and 30-60% of female prisoners. The spread of hepatitis C in prisons is clearly driven by injection drug use, with many infected prisoners unaware of their infection status. Risk behaviour for acquisition of hepatitis C via common use of injecting equipment is widespread in many prison settings. In custodial settings, effective and efficient prevention models applied in the community are very rarely implemented. Only approximately 60 out of more than 10,000 prisons worldwide provide needle exchange. Thus, HCV prevention is almost exclusively limited to verbal advice, leaflets and other measures directed to cognitive behavioural change. Although the outcome of HCV antiviral treatment is comparable to non-substance users and substance users out of prison, the uptake for antiviral treatment is extremely low. Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the impact for the prison system, recommendations regarding hepatitis C prevention, screening and treatment in prisons have been formulated in this article.